• 1. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 2. Excess electrons in lithium–ethylamine solutions—density, electrical conductivity and EPR studies
  Phys. Chem. Chem. Phys., 1999,1, 3561-3565
• 3. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 4. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 5. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Alkanolamines

Research Update on Ethanol, 2-[(2-hydrazinoethyl)amino]- (CAS: 88303-65-5) in Chemical Biology and Pharmaceutical Applications

The compound Ethanol, 2-[(2-hydrazinoethyl)amino]-, bearing the CAS registry number 88303-65-5, has recently garnered significant attention in chemical biology and pharmaceutical research due to its unique bifunctional structure combining hydrazine and ethanolamine moieties. This hybrid molecule serves as a versatile building block in medicinal chemistry, particularly in the development of targeted drug conjugates and bioorthogonal probes. Recent studies highlight its role as a key intermediate in synthesizing hydrazone-based prodrugs, where the hydrazino group enables pH-sensitive drug release in tumor microenvironments.

A 2023 study published in Journal of Medicinal Chemistry demonstrated the compound's utility in creating antibody-drug conjugates (ADCs) with improved stability profiles. Researchers utilized 88303-65-5 as a linker component connecting monoclonal antibodies to cytotoxic payloads, achieving enhanced serum stability while maintaining efficient payload release at target sites. The ethanolamine spacer was found to significantly reduce aggregation issues common in ADC formulations, addressing a major challenge in bioconjugate therapeutics.

In neuropharmacology applications, derivatives of Ethanol, 2-[(2-hydrazinoethyl)amino]- have shown promise as MAO-B inhibitors. A preclinical study in ACS Chemical Neuroscience (2024) reported novel hydrazine-containing analogs exhibiting selective inhibition of monoamine oxidase B with IC50 values in the nanomolar range. The ethanolamine side chain appears to contribute to blood-brain barrier penetration, making these derivatives potential candidates for neurodegenerative disease treatment.

The compound's reactivity has also been exploited in bioimaging applications. A recent Chemical Communications paper detailed its use as a precursor for developing turn-on fluorescent probes targeting cellular carbonyl species. The hydrazino group specifically reacts with aldehydes and ketones, while the ethanolamine moiety enhances water solubility - a combination that enables real-time monitoring of oxidative stress biomarkers in live cells with minimal background interference.

From a synthetic chemistry perspective, advances in the production of 88303-65-5 have been reported. A 2024 Organic Process Research & Development article described a continuous flow synthesis method that improves yield (82% vs. traditional batch's 65%) while reducing hydrazine exposure risks. This technological advancement supports safer large-scale production to meet growing demand from pharmaceutical developers.

Ongoing clinical trials (as of Q2 2024) include three Phase I studies investigating 88303-65-5-containing prodrugs for oncology indications, particularly focusing on its use in hypoxia-activated therapeutics. The compound's ability to form stable conjugates that selectively release drugs under low oxygen conditions (characteristic of solid tumors) positions it as a valuable component in next-generation targeted cancer therapies.

Future research directions highlighted in recent reviews point to unexplored potential in antimicrobial applications, where the hydrazine-ethanolamine hybrid structure may offer novel mechanisms against drug-resistant pathogens. Computational studies suggest possible interactions with bacterial metalloenzymes, warranting further experimental investigation.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)